Allogene Therapeutics (ALLO) Capital Expenditures (2018 - 2026)

Allogene Therapeutics has disclosed Capital Expenditures across 9 years of filings, most recently posting $9000.0 for Q1 2026.

• Capital Expenditures for Q1 2026 came in at $9000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $116000.0 (down 83.09% YoY), and the FY2025 annual result was $107000.0, down 84.58% from the prior year.
• Capital Expenditures came in at $9000.0 for Q1 2026 at Allogene Therapeutics, up from -$279000.0 in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $1.9 million in Q1 2022 to a low of -$2.8 million in Q4 2022.
• The 5-year median for Capital Expenditures is $215000.0 (2025), against an average of $200266.7.
• Across the five-year window, Capital Expenditures surged 3475.0% in 2024 and plunged 208.56% in 2025, its largest moves.
• Allogene Therapeutics' Capital Expenditures stood at -$2.8 million in 2022, then soared by 106.42% to $181000.0 in 2023, then surged by 41.99% to $257000.0 in 2024, then slumped by 208.56% to -$279000.0 in 2025, then jumped by 103.23% to $9000.0 in 2026.
• The last three Capital Expenditures figures came in at $9000.0 (Q1 2026), -$279000.0 (Q4 2025), and $171000.0 (Q3 2025), per Business Quant data.